Non-interventional Prospective Observational Study of Cytoflavin in Combination With Reperfusion in Stroke Patients

Condition:   Acute Stroke Interventions:   Drug: Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin);   Drug: Control Sponsor:   POLYSAN Scientific& Technological Pharmaceutical Company Not yet recruiting

Source: ClinicalTrials.gov - March 28, 2022 Category: Research Source Type: clinical trials